Companies
Merz Pharma
the complexing-protein-free "naked toxin" BoNT-A, manufactured via Merz's proprietary purification technology that removes accessory proteins during production; approved in 79 countries for therapeutic and aesthetic indications, with EU EMA submission (January 26,…
- Country
- Germany
Japan MHLW cervical dystonia + blepharospasm approval June 19, 2026; EU pediatric spasticity EMA submission Jan 26, 2026
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | EUR 1.3434 billion (fiscal year 2021/22) | merz.com |
| Production site | Dessau, Germany | merz.com |
| Regulatory approval | Xeomin (incobotulinumtoxinA) has various approvals including FDA (2011, 2024) and Japan MHLW (2020) for indications such as glabellar lines, upper facial lines, and limb spasticity | finance.yahoo.com · merztherapeutics.com · mineclinic.com · delveinsight.com · researchandmarkets.com |
| Certification | Great Place to Work Certification (Merz Therapeutics North America, 2023) | merztherapeutics.com |
| Funding | Not publicly specified as a standalone funding round for this private, long-established company; consolidated financial results are reported annually. medium confidence | delveinsight.com · researchandmarkets.com |
| Capacity | Specific numerical capacity is not publicly disclosed; manufacturing utilizes proprietary XTRACT purification technology in a dedicated facility in Dessau. medium confidence | dataintelo.com · merz.com |
Independent sources: dataintelo.com · delveinsight.com · finance.yahoo.com · merztherapeutics.com · mineclinic.com · researchandmarkets.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant botulinum toxin (biosynthetic Botox) | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.